

Invega Sustenna® Review

1. You are preparing to administer Invega Sustenna® to a patient who weighs 146 pounds. What size needle will you use?

1" 23g

2. Name the most common side effects a patient may experience when taking Invega Sustenna®.

Injection site reactions, sleepiness or drowsiness, restless
constant moving, abnormal muscle movements (tremors, shuffling)
uncontrolled moving
abnormal movement of eyes

3. What black box warning is associated with this medication?

Increased mortality in elderly pt's w/ dementia - Related psychosis

4. What are the standard recommended Day 1 and Day 8 initiation dosages for a person with schizophrenia?

Day 1 / 234mg Day 8 / 150mg

5. What is the standard recommended maintenance dosage for a patient with schizophrenia?

117mg

6. What is the correct location for administration of the Day 1 and Day 8 initiation doses?

Deltoid muscle

7. What are the recommended Day 1 and Day 8 initiation dosages for a person with a creatinine clearance of 65mL/min?

Day 1 150mg Day 8 117mg

8. What would the *recommended* maintenance dosage be for a patient with mild renal impairment?

70mg once monthly

9. What is the rationale for a trial of oral paliperidone or oral or injectable risperidone before placing a patient on Invega Sustenna®?

monitoring side effects

assess therapeutic response

pt adherence and tolerability

10. Name three practices when preparing an intramuscular injection that ensure aseptic technique is maintained throughout the procedure.

hand hygiene

sterile equipment

clean injection site

11. Explain the rationale for obtaining consent for this psychoactive medication prior to preparing the medication for administration.

Risk disclosure and pt understanding

legal and professional accountability to pt's

rights and the clinician's integrity